IL17A and psoriasis: The use of anti-IL17 monoclonal antibodies has shown great efficacy in psoriasis patients [[43], [44], [45]], besides the reduction in PASI scores, this therapy has been shown to influence various disease parameters, such as skin microbiota composition [46], histological features [47], and immune-related genes [47].